These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 32921987)

  • 1. Fatostatin in Combination with Tamoxifen Induces Synergistic Inhibition in ER-Positive Breast Cancer.
    Liu Y; Zhang N; Zhang H; Wang L; Duan Y; Wang X; Chen T; Liang Y; Li Y; Song X; Li C; Han D; Chen B; Zhao W; Yang Q
    Drug Des Devel Ther; 2020; 14():3535-3545. PubMed ID: 32921987
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dual inhibition of PI3K and mTOR mitigates compensatory AKT activation and improves tamoxifen response in breast cancer.
    Chen X; Zhao M; Hao M; Sun X; Wang J; Mao Y; Zu L; Liu J; Shen Y; Wang J; Shen K
    Mol Cancer Res; 2013 Oct; 11(10):1269-78. PubMed ID: 23814023
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Huaier extract synergizes with tamoxifen to induce autophagy and apoptosis in ER-positive breast cancer cells.
    Qi W; Sun M; Kong X; Li Y; Wang X; Lv S; Ding X; Gao S; Cun J; Cai C; Wang X; Chen J; Yin A; Yang Q
    Oncotarget; 2016 May; 7(18):26003-15. PubMed ID: 27027343
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Baicalein induces apoptosis and autophagy of breast cancer cells via inhibiting PI3K/AKT pathway in vivo and vitro.
    Yan W; Ma X; Zhao X; Zhang S
    Drug Des Devel Ther; 2018; 12():3961-3972. PubMed ID: 30510404
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metformin enhances tamoxifen-mediated tumor growth inhibition in ER-positive breast carcinoma.
    Ma J; Guo Y; Chen S; Zhong C; Xue Y; Zhang Y; Lai X; Wei Y; Yu S; Zhang J; Liu W
    BMC Cancer; 2014 Mar; 14():172. PubMed ID: 24612549
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of dual mTORC1/2 mTOR kinase inhibitor AZD8055 on acquired endocrine resistance in breast cancer in vitro.
    Jordan NJ; Dutkowski CM; Barrow D; Mottram HJ; Hutcheson IR; Nicholson RI; Guichard SM; Gee JM
    Breast Cancer Res; 2014 Jan; 16(1):R12. PubMed ID: 24457069
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Synergistic Effects of Celastrol in combination with Tamoxifen on Apoptosis and Autophagy in MCF-7 Cells.
    Wang L; Tang L; Yao C; Liu C; Shu Y
    J Immunol Res; 2021; 2021():5532269. PubMed ID: 34337076
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MDM2 inhibition in combination with endocrine therapy and CDK4/6 inhibition for the treatment of ER-positive breast cancer.
    Portman N; Milioli HH; Alexandrou S; Coulson R; Yong A; Fernandez KJ; Chia KM; Halilovic E; Segara D; Parker A; Haupt S; Haupt Y; Tilley WD; Swarbrick A; Caldon CE; Lim E
    Breast Cancer Res; 2020 Aug; 22(1):87. PubMed ID: 32787886
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting tyrosine-kinases and estrogen receptor abrogates resistance to endocrine therapy in breast cancer.
    Liu S; Meng X; Chen H; Liu W; Miller T; Murph M; Lu Y; Zhang F; Gagea M; Arteaga CL; Mills GB; Meric-Bernstam F; González-Angulo AM
    Oncotarget; 2014 Oct; 5(19):9049-64. PubMed ID: 24979294
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IGF-1R pathway activation as putative biomarker for linsitinib therapy to revert tamoxifen resistance in ER-positive breast cancer.
    Kruger DT; Alexi X; Opdam M; Schuurman K; Voorwerk L; Sanders J; van der Noort V; Boven E; Zwart W; Linn SC
    Int J Cancer; 2020 Apr; 146(8):2348-2359. PubMed ID: 31490549
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hedgehog signaling is a novel therapeutic target in tamoxifen-resistant breast cancer aberrantly activated by PI3K/AKT pathway.
    Ramaswamy B; Lu Y; Teng KY; Nuovo G; Li X; Shapiro CL; Majumder S
    Cancer Res; 2012 Oct; 72(19):5048-59. PubMed ID: 22875023
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer.
    Shou J; Massarweh S; Osborne CK; Wakeling AE; Ali S; Weiss H; Schiff R
    J Natl Cancer Inst; 2004 Jun; 96(12):926-35. PubMed ID: 15199112
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined histone deacetylase inhibition and tamoxifen induces apoptosis in tamoxifen-resistant breast cancer models, by reversing Bcl-2 overexpression.
    Raha P; Thomas S; Thurn KT; Park J; Munster PN
    Breast Cancer Res; 2015 Feb; 17(1):26. PubMed ID: 25848915
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibiting PAD2 enhances the anti-tumor effect of docetaxel in tamoxifen-resistant breast cancer cells.
    Li F; Miao L; Xue T; Qin H; Mondal S; Thompson PR; Coonrod SA; Liu X; Zhang X
    J Exp Clin Cancer Res; 2019 Oct; 38(1):414. PubMed ID: 31601253
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rapamycin inhibits proliferation of estrogen-receptor-positive breast cancer cells.
    Chang SB; Miron P; Miron A; Iglehart JD
    J Surg Res; 2007 Mar; 138(1):37-44. PubMed ID: 17109887
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synergistic anti-cancer activity of CDK4/6 inhibitor palbociclib and dual mTOR kinase inhibitor MLN0128 in pRb-expressing ER-negative breast cancer.
    Yamamoto T; Kanaya N; Somlo G; Chen S
    Breast Cancer Res Treat; 2019 Apr; 174(3):615-625. PubMed ID: 30607633
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disruption of Cancer Metabolic SREBP1/miR-142-5p Suppresses Epithelial-Mesenchymal Transition and Stemness in Esophageal Carcinoma.
    Huang CM; Huang CS; Hsu TN; Huang MS; Fong IH; Lee WH; Liu SC
    Cells; 2019 Dec; 9(1):. PubMed ID: 31861383
    [No Abstract]   [Full Text] [Related]  

  • 18. Tamoxifen resistance alters sensitivity to 5-fluorouracil in a subset of estrogen receptor-positive breast cancer.
    Watanabe T; Oba T; Tanimoto K; Shibata T; Kamijo S; Ito KI
    PLoS One; 2021; 16(6):e0252822. PubMed ID: 34101751
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of STAT3 enhances sensitivity to tamoxifen in tamoxifen-resistant breast cancer cells.
    Moon SY; Lee H; Kim S; Hong JH; Chun SH; Lee HY; Kang K; Kim HS; Won HS; Ko YH
    BMC Cancer; 2021 Aug; 21(1):931. PubMed ID: 34407787
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Autocrine IGF-I/insulin receptor axis compensates for inhibition of AKT in ER-positive breast cancer cells with resistance to estrogen deprivation.
    Fox EM; Kuba MG; Miller TW; Davies BR; Arteaga CL
    Breast Cancer Res; 2013; 15(4):R55. PubMed ID: 23844554
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.